Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study Evaluating the Probability of OncotypeDx to Allocate At Low or High Risk of Recurrence Early ER Positive HER2 Negative Breast Cancer Patients with Uncertain Biological Behavior Evaluated by Pathological Parameters

NCT06363812 is registered in ClinicalTrials.gov with Fondazione Sandro Pitigliani as lead sponsor.

NCT NCT06363812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06363812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study Evaluating the Probability of OncotypeDx to Allocate At Low or High Risk of Recurrence Early ER Positive HER2 Negative Breast Cancer Patients with Uncertain Biological Behavior Evaluated by Pathological Parameters
Lead sponsor
Fondazione Sandro Pitigliani
Phase
Observational
Overall status
Completed
Start date
March 8, 2018
Completion date
December 31, 2024
Enrollment
258 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer